Compare HUMA & KINS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HUMA | KINS |
|---|---|---|
| Founded | 2004 | 1886 |
| Country | United States | United States |
| Employees | 220 | 113 |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.4M | 205.7M |
| IPO Year | N/A | 2013 |
| Metric | HUMA | KINS |
|---|---|---|
| Price | $0.68 | $14.21 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $9.29 | N/A |
| AVG Volume (30 Days) | ★ 8.0M | 88.5K |
| Earning Date | 03-27-2026 | 03-05-2026 |
| Dividend Yield | N/A | ★ 1.36% |
| EPS Growth | N/A | ★ 94.59 |
| EPS | N/A | ★ 2.88 |
| Revenue | N/A | ★ $214,867,301.00 |
| Revenue This Year | N/A | $10.53 |
| Revenue Next Year | $731.05 | $15.00 |
| P/E Ratio | ★ N/A | $5.09 |
| Revenue Growth | N/A | ★ 38.50 |
| 52 Week Low | $0.70 | $13.08 |
| 52 Week High | $2.93 | $22.20 |
| Indicator | HUMA | KINS |
|---|---|---|
| Relative Strength Index (RSI) | 31.26 | 33.72 |
| Support Level | N/A | $13.22 |
| Resistance Level | $1.30 | $15.58 |
| Average True Range (ATR) | 0.10 | 0.50 |
| MACD | -0.04 | -0.09 |
| Stochastic Oscillator | 2.03 | 8.91 |
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
Kingstone Companies Inc offers property and casualty insurance products through its subsidiary engaged in writing business through retail and wholesale agents and brokers. Its products include Personal lines, Livery physical damage, and Others. It operates in single segment, property and casualty insurance. It derives substantially all of its revenue from KICO, including revenues from earned premiums, ceding commissions from quota share reinsurance, net investment income generated from its investment portfolio, and net realized gains and losses on investment securities.